<SEC-DOCUMENT>0001193125-23-256085.txt : 20231013
<SEC-HEADER>0001193125-23-256085.hdr.sgml : 20231013
<ACCEPTANCE-DATETIME>20231013160801
ACCESSION NUMBER:		0001193125-23-256085
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20231013
FILED AS OF DATE:		20231013
DATE AS OF CHANGE:		20231013

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		231325166

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d565918d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2023 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&nbsp;&#9745;&#8195;&#8195;&#8195;&#8195; Form
<FONT STYLE="white-space:nowrap">40-F&#8194;&nbsp;&#9744;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;13, 2023, Kazia Therapeutics Limited (the &#147;Company&#148;) filed a release with the Australian Securities
Exchange (&#147;ASX&#148;), as required by the laws and regulations of Australia, updating the Shareholders about the ASX de-listing process. The announcement and the Shareholder Communication Letter are both furnished herewith as Exhibits&nbsp;99.1
and 99.2, respectively, to this report on <FONT STYLE="white-space:nowrap">Form&nbsp;6-K.</FONT> A copy of the ADS Conversion Facility Election Form is available on the Company&#146;s website. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d565918dex991.htm">Shareholder Communication Announcement of Kazia Therapeutics Limited dated October 13, 2023 </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d565918dex992.htm">Shareholder Communication Letter of Kazia Therapeutics Limited dated October 13, 2023 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October&nbsp;13, 2023</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d565918dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g565918g1011060824196.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX RELEASE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13&nbsp;October
2023 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SHAREHOLDER COMMUNICATION ON </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THE <FONT STYLE="white-space:nowrap">DE-LISTING</FONT> PROCESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 13</B><B></B><B>&nbsp;October 2023</B> &#150; Kazia Therapeutics Limited (<B>Kazia</B> or the <B>Company</B>) NASDAQ: KZIA; ASX: KZA), an
oncology-focused drug development company, refers to its Announcement released to the ASX on 11&nbsp;October 2023 titled &#147;Kazia announces voluntary delisting from ASX&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with ASX Listing Rule 3.17, please find attached copies of the following documents being sent to Shareholders today: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">A letter giving information about the <FONT STYLE="white-space:nowrap">de-listing</FONT> process and the options
available to Shareholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">An ADS Conversion Facility Election Form. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Updated Timetable </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company also advises that an
updated timetable for the <FONT STYLE="white-space:nowrap">de-listing</FONT> is set out below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="14%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Event</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Indicative Date*</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification of intention to delist</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">11&nbsp;October&nbsp;2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Despatch
of letters and ADS Conversion Facility election forms to shareholders</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">13&nbsp;October 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing
Date: Participation in ADS Conversion Facility</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">13&nbsp;November&nbsp;2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Last day
for trading of the Company&#146;s Shares on ASX</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">13&nbsp;November 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Completion of removal of the Company from the Official List of the ASX</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">15&nbsp;November 2023</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">*Dates and times are indicative only and subject to change by the Company or ASX. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the Company Secretary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Enquiries: </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>cosec@companymatters.com.au </U></B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of Directors </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr John Friend</B> Interim
Executive Chair and Chief Executive Officer<B> </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Bryce Carmine </B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director<B> </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Mr Steven Coffey </B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director<B> </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Ms Ebru Davidson </B><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Director </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Three International Towers, Level&nbsp;24, 300 Barangaroo Avenue, Sydney NSW 2000 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase II study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study in
glioblastoma, GBM AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the FDA in
August 2020. Paxalisib was also awarded Fast Track Designation (FTD) in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare
Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A Phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit <U>www.kaziatherapeutics.com</U> or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward- looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801. Such statements are based on Kazia&#146;s current
expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking
statements, including risks and uncertainties: associated with clinical and preclinical trials and product development, related to regulatory approvals, related to Kazia&#146;s executive leadership changes, and related to the impact of global
economic conditions.. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United States
Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place
undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d565918dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g565918g1011060824196.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>13&nbsp;October 2023 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Shareholder </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited (ASX:KZA,
NASDAQ:KZIA) &#150; Voluntary delisting from the ASX </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (ASX:KZA, NASDAQ:KZIA) (<B>Kazia</B> or the <B>Company</B>) has
requested and received formal approval from the Australian Securities Exchange (<B>ASX</B>) to be removed from the official list of the ASX (<B>Official List</B>) pursuant to ASX Listing Rule 17.11 (<B>Delisting</B>). This letter seeks to provide
you, as a holder of fully paid ordinary shares in the capital of the Company (<B>Shares</B>), with information about the Delisting process, the options available to you in connection with your Shares and certain implications which may arise for you
as a result of the Delisting. Full details regarding the options available to you in respect of your Shares are set out in Section&nbsp;5. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
information in this letter does not take into account your individual investment objectives, financial situation and needs. The information in this letter is of a general nature and is not financial product advice and should not be relied upon as
the sole basis for any investment decision. As a holder of Shares (<B>Shareholder</B>), you should consult your financial, legal, tax or other professional advisor in relation to the information contained in this letter and how you should act with
respect to your Shares. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Why is Kazia delisting from the ASX? </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has ultimately determined that the costs, administrative burden and commercial disadvantages of remaining listed on ASX outweigh any benefits of a
continued ASX listing. The Board considers that the Delisting is in the best interests of the Company and Shareholders for the following reasons. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Costs: The continued listing of Kazia on ASX requires it to incur considerable corporate and administrative
costs, including listing fees. Kazia is seeking to minimise its expenditure and would cease incurring such additional costs if it is removed from the Official List. The Company considers the financial, administrative and compliance obligations and
costs associated with managing an ASX listing and a NASDAQ listing, including the higher level of regulatory compliance costs associated with a dual listing, noting that there are a number of material differences between the NASDAQ listing rules and
the ASX listing rules, unjustifiable and not in the best interests of the Company&#146;s securityholders. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Access to larger equity markets with biotechnology focus: The Board believes that Delisting from ASX whilst
retaining the NASDAQ listing will enable Kazia to have access to a deeper market that better understands, and values, biotechnology businesses, thereby allowing it to more readily raise more capital on better terms, from a wider investor base. This
access is pivotal in assisting Kazia to raise appropriate growth capital to pursue its plans. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Capital raisings: The Delisting from ASX and retention of a primary listing on NASDAQ is expected to improve
the Company&#146;s access to its institutional investor base and other financing options in the USA that currently has the most active biotechnology ecosystem on a global basis. Being dual listed on ASX and NASDAQ is currently limiting fundraising
options for Kazia. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Location of directors and management: With the exception of two
<FONT STYLE="white-space:nowrap">non-executive</FONT> directors, the Company&#146;s remaining <FONT STYLE="white-space:nowrap">non-executive</FONT> board member, Karen Krumeich, the Company&#146;s Chief Financial Officer and Dr John Friend, the
Company&#146;s CEO, Managing Director and Interim Chairman, are now based in the USA, reflecting the Company&#146;s focus on international rather than domestic markets. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are the consequences of Delisting? </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The main consequence of Delisting for Shareholders is that, from the time the Delisting takes effect on 15&nbsp;November 2023 (Delisting Date), Kazia&#146;s
Shares will no longer be quoted or traded on the ASX. Therefore, Shareholders who wish to sell their Shares on the ASX will need to do so before the Delisting Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders who retain their Shares after the Delisting Date will each be issued a share certificate which will be proof of ownership of their Shares and
should be held in safe-keeping by the Shareholder. Shareholders who wish to sell their Shares after the Delisting Date must either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">convert their Shares to American Depositary Shares (ADSs) and sell their ADSs on NASDAQ by setting up an
account with a US Broker, either by a direct engagement or through an Australian broker who has an agreement with a US broker that is able to buy or sell ADSs on NASDAQ; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sell their Shares via <FONT STYLE="white-space:nowrap">off-market</FONT> private transactions (subject to
compliance with the <I>Corporations Act 2001 </I>(Cth)). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Following the Delisting, Kazia will remain an Australian incorporated company
and will maintain its listing of ADSs on NASDAQ. Trading of ADSs on NASDAQ will continue, uninterrupted, during and after the Delisting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of
Kazia&#146;s press releases and other corporate information will continue to be available on the US Securities and Exchange Commission&#146;s (SEC) website (<U>www.sec.gov</U>) as well as the Company&#146;s website at
<U>https://www.kaziatherapeutics.com/</U>. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are ADSs? </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each ADS represents the right to receive, and to exercise the beneficial ownership interests in, 10 Shares that are on deposit with HSBC Custody Nominees
(Australia) Limited (Custodian), the custodian appointed by the Depositary. The Depositary will be (directly or indirectly through the Custodian) the holder of the Shares underlying the ADSs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of ADSs do not have direct Shareholder rights. The Depositary holds, on the ADS holder&#146;s behalf, the rights attaching to the Shares underlying
your ADSs. Holders of ADSs are able to exercise the rights attaching to the Shares represented by the ADSs through the Depositary to the extent contemplated in the deposit agreement (Deposit Agreement), a copy of which is available from the
SEC&#146;s website (<U>www.sec.gov</U>). To exercise any rights attaching to Shares which are not contemplated under the Deposit Agreement, holders of ADSs will need to arrange for the cancellation of their ADSs so that they can become a direct
Shareholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares represented by ADSs are treated as held under a bare trust for such holder. Consequently, the Shares will be regarded as owned by the
ADS holder for Australian income tax and capital gains tax purposes. Dividends paid on the underlying Shares will also be treated as dividends paid to the ADS holder, as the person beneficially entitled to those dividends. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What is the Delisting process and timetable? </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Delisting process</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Shareholders will continue to be able to trade their Shares on the ASX until the close of trading on 13&nbsp;November 2023 (Suspension Date),
when trading in Shares will be suspended. Following suspension of Shares from quotation, Shareholders will no longer be able to trade their Shares on the ASX. It is expected that two business days following the suspension of trading of Shares, Kazia
will be removed from the Official List. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Shareholders who retain their Shares after the Delisting Date will be issued share certificates,
which will be proof of ownership of their Shares and should be held in safe-keeping by the Shareholder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>ADS Conversion Facility</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The Company has established a facility pursuant to which Shareholders may elect to convert, prior to the Delisting, all of their Shares to ADS
(ADS Conversion Facility), unless they are a custodian or nominee holding Shares on behalf of multiple holders in which case partial elections will be permitted. If the number of Shares held by a Shareholder is such that the aggregate entitlement of
the Shareholder includes a fractional entitlement to an ADS, then the entitlement of that Shareholder will be rounded down to the nearest whole number of ADSs and the Shareholder will retain the remaining Shares held which are not converted to ADSs.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The ADS conversion fee will be waived during the time-limited period in which the ADS Conversion Facility will be active. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">See section 5 below for details on how to participate, prior to the Delisting, in the ADS Conversion Facility. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Indicative dates for the Delisting process</U> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">The table below sets out an indicative timeline for the Delisting process. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="96%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="15%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">Event</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">Indicative&nbsp;Date*</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Notification of intention to delist</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">11&nbsp;October&nbsp;2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Despatch
of letters and ADS Conversion Facility election forms to shareholders (in relation to the ADS Conversion Facility)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">13&nbsp;October 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Closing
Date: Participation in ADS Conversion Facility</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">13&nbsp;November&nbsp;2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Last day
for trading of the Company&#146;s Shares on ASX</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">13&nbsp;November 2023</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Completion of removal of the Company from the Official List of the ASX</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt">15&nbsp;November 2023</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">*All dates and times in this letter refer to those in Sydney, Australia. These dates and times are
indicative only and subject to change. Kazia will announce any amendment to those dates and times. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>What are my options? </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a holder of Shares, you have the following options in respect of the Delisting, which you should carefully consider before deciding what to do with your
Shares. If you do nothing, then Option 3 will apply by default. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman">&#8194;OPTION 1: Sell your Shares on ASX on or before the Suspension Date </P></div>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can sell your Shares on the ASX at any time prior to the close of trading on the Suspension Date, which is currently expected to be 13&nbsp;November 2023.
You should contact your stockbroker or financial advisor to arrange the sale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the Suspension Date, you will not be able to sell your Shares on the
ASX. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you elect to sell your Shares on the ASX prior to the Suspension Date, you will be responsible for all costs associated with the sale, including
any broker commission. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman">&#8194;OPTION 2: Convert your Shares to ADSs </P></div>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can elect to participate in the ADS Conversion Facility and convert all of your Shares into ADSs on a 10:1 basis, unless you are a custodian or nominee
holding Shares on behalf of multiple holders in which case partial elections will be permitted, to be held directly in uncertificated form in the Direct Registration System (DRS) on the American Depositary Receipt (ADR) register of the Depositary.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the number of Shares held by a Shareholder is such that the aggregate entitlement of the Shareholder includes a fractional entitlement to an ADS, then
the entitlement of that Shareholder will be rounded down to the nearest whole number of ADSs and the Shareholder will retain the remaining Shares held which are not converted to ADSs (Remaining Shares). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders will be waived from the conversion fee if they convert their Shares into ADSs by participating in the ADS Conversion Facility no later than the
Suspension Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shareholders who would like to participate in the ADS Conversion Facility should complete an ADS Conversion Facility election form
(Conversion Form) and return it to the Company&#146;s Australian Share Registry, Computershare Investor Services Pty Limited (Computershare), by no later than the Suspension Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you return your Conversion Form after the Suspension Date, you will not be able to participate in the ADS Conversion Facility. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you elect to convert your Shares into ADSs, you may then choose to hold those ADSs or sell them on the NASDAQ at a later time through a US broker or an
Australian broker who has an agreement with a US broker that is able to buy or sell ADSs on NASDAQ (subject to compliance with NASDAQ trading requirements). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you elect to participate in the ADS Conversion Facility and then subsequently sell your ADSs on NASDAQ, any costs incurred in connection with the sale will
be borne by you. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you do not elect to participate in the ADS Conversion Facility, you can elect, either prior to the Delisting or after, to convert
your Shares to ADSs. In such a case, all related costs will be borne by you. In order to do this, you need to engage a US broker or an Australian broker who has an agreement with a US broker that is able to buy or sell ADSs on Nasdaq. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1px;background-color:;;padding-top:2pt;padding-bottom:3pt">
<P STYLE="margin-top:0pt; margin-bottom:0pt; padding-top:0pt; font-size:10pt; font-family:Times New Roman">&#8194;OPTION 3: Take no action by the Suspension Date </P></div>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you take no action by the Suspension Date (i.e. you do not proceed with Option 1 or Option 2 above), you will retain your Shares but they will no longer be
quoted, or able to be traded on the ASX and your Shareholding will become a certificated holding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you take no action, a share certificate will be
issued for your Shares and be sent to you by post within approximately 10 business days of the Delisting Date. This must be kept in a safe place as it is proof of ownership of Shares in the Company. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Risks </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are risks associated with participating in the ADS Conversion Facility and holding ADSs. If you elect to participate in the ADS Conversion Facility you
will be issued ADSs and be subject to the rights and obligations of an ADS holder. Therefore, the Company strongly encourages you to read the section of the Company&#146;s Form <FONT STYLE="white-space:nowrap">F-3</FONT> Registration Statement,
which includes a summary description of the material terms of the ADSs and of the material rights of owners of ADSs. A copy of the Company&#146;s Form <FONT STYLE="white-space:nowrap">F-3</FONT> Registration Statement is available on the US
Securities and Exchange Commission&#146;s (SEC) website (<U>www.sec.gov</U>) as well as the Company&#146;s website at <U>https://www.kaziatherapeutics.com/</U>. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>7.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Restrictions on certain Shareholders </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this letter to the contrary, Shareholders who either: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">are, or have been during the three months prior to completion of the Conversion Form, as applicable, an officer
or director of the Company, a beneficial owner of Shares representing 10% or more of the voting power of the capital stock of the Company or an &#147;affiliate&#148; of the Company within the meaning of Rule 144 under the US Securities Act of 1933,
as amended (Securities Act) (each, an Affiliate); or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">or were issued or acquired Shares from the Company or an Affiliate in transactions other than a public
registered offering within a year prior to the completion of the Conversion Form, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and obtain ADSs as a result of participating in the
ADS Conversion Facility will be subject to certain resale restrictions pursuant to the Securities Act. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>8.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Tax implications </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not address any tax or duty consequences other than Australian income tax consequences to Shareholders that are Australian tax residents
from participation in the ADS Conversion Facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discussion does not address any Australian tax consequences for persons that are not Australian
residents for tax purposes nor does it address any US state or local tax consequences or any US federal income tax consequences. Shareholders should consult their tax advisors regarding any income or other tax consequences which may result from
participation in the ADS Conversion Facility. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Australian income tax consequences </U></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a general description of the Australian income tax consequences for Shareholders who are individuals, complying superannuation funds or
private companies and are Australian tax residents, which result from participation in the ADS Conversion Facility. It is not intended to be a comprehensive statement of the Australian income tax consequences of participating in the ADS Conversion
Facility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The general description below only applies to Shareholders who hold their Shares on capital account for Australian income tax purposes and are
an Australian resident for tax purposes. In particular, it does not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shareholders who buy and sell shares in the ordinary course of business (i.e. Shareholders who hold their
Shares on revenue account); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shareholders who hold their Shares as trading stock for Australian income tax purposes; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Shareholders that are subject to the taxation of financial arrangements rules in Division 230 of the <I>Income
Tax Assessment Act 1997 </I>(Cth) in relation to gains and losses on their Shares.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information is based upon Australian taxation law and practice in effect at the date of this letter. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Division 230 will generally not apply to individuals, unless they have made an election for it to apply to
them. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company strongly encourages Shareholders to obtain their own tax advice based on the Shareholder&#146;s
particular circumstances before deciding which option to select. The general description of the Australian income tax consequences for Shareholders does not purport to provide Shareholders with any tax advice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Participation in the ADS Conversion Facility </U></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is not
anticipated the Shareholders will make a capital gain or capital loss as a result of participating in the ADS Conversion Facility. This is on the basis the Shareholders will continue to be the beneficial owners of the Shares as the ADS Conversion
Facility is a bare trust arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Shareholder&#146;s cost base or reduced cost base in the ADSs they receive as a consequence of participating in
the ADS Conversion Facility should be equal to the cost base or reduced cost base of the Shareholder&#146;s Shares at the time of the conversion of the Shares into ADSs. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>9.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Further information </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you have a question in relation to the Delisting or any information set out in this letter please contact your tax advisor or Anna Sandham, Corporate
Secretary at <U>cosec@companymatters.com.au</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yours sincerely, </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr.&nbsp;John Friend </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Interim Chairman and Chief
Executive Officer </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g565918g1011060824196.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g565918g1011060824196.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !X Q8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J_HVG#5-12V:38I!9B.N!Z
M50KJH?#GD:.NI17DB72Q><"O"CC./RK2G%R>VQC7J*$;7LWL1W2/X2U%'M7\
MZ.=""DG7@^U9-_>7>JW37K1L-H !C!P@'O21I>:U=$R3%W5>7D/05<BU Z5!
M)92P[I$)P0>#GUK&OB'?DIZ^1VX+ 1:57$NRLUS6W?;^NQ3ATRZN[9KH,".2
M-QY;%01-=+(EV@D8Q,")""0".E/AU&Y@MFMXY,1G/;D9]*MVNK"+3OL@AW2$
M%5.>#GU_.LG*M&[M?7\#IC3P551C=Q]W6^MWV1=.IW/B>ZMM.E$<$;-N8KSD
M@'U_&J_B#0X](,+0RLZ2Y&'QD$8_QJI<Z==:8L=QY@!#<,A.5-;6F:0_B&T-
MY?WLS."40 CY<>M=E.<:\7RZON>3B*$\%-*?NI=/4Y6BI)XC!<2PDAC&Y7([
MX.*CK,V3OJ>K3_#+1H_ AUL75]]J&GBZVETV;MF[&-N<?C7(>"?!\_BW5?+)
M>*QAYN)E'(]%'^T?_KU[;;V$FJ?#:WL(F59+G2TB5FZ F,#)JCJ%UIOPR\%)
M';1[Y!\D0(YFE(Y9ORS]!@5@IO;J;N"WZ'F7Q \+^'O"IM[33[N\FU!SOD25
MU94CQWPHY)Z>V?:N&JQ?7MSJ5]->W<K2W$S%W=NYJO6J32U,F[O0*[IOA_(O
MPW'B',GVW/GF+MY'3./7^+/I7/\ A30W\1>)+/3@#Y;ONF8?PQCEC^7'U(KZ
M4+6+,VDDQ9\C)M_^F1^7IZ=JB<[;%PC?<^4:*V/%&B2>'O$=YIK9V1OF)C_$
MAY4_E^N:QZT3N9O0]"^'G@73/%EA>W%_/=QM!*$40.H&",\Y4UV7_"F?#G_/
MYJ?_ ']C_P#B*\1AN[FV!$%Q+%NZ^6Y7/Y5[[X"L'\.^#&U+5KB3S9T-S,TK
MD^7&!E1S[<_4UE.ZUN:PL]+'F/Q#\+Z+X4N;.TTZYNI;F13)*LSJP5>B]%')
M.?RKBJT_$.LS:_KUWJ<V09GRJD_=4<*/P&*S*TC>VIG*U]#U+PC\-M'U_P (
M0ZM=7-\EQ(),K$Z!1M8@<%2>WK7EM?0GPU_Y)K:?2;_T-J^>ZF#;;*FDD@K3
M\/:-+K^O6>F19'GR8=A_"HY8_@ :S*]D^#F@""RNM?N%PTV88">R#[Q_$C'_
M  $TY2LKDQ5W8X'QUX7'A7Q"UI"7:SE020,YR<=""?4'/Z5S->^?$C28/$W@
MM=4L669[5?M,+ISOC(^8?ES_ ,!KP.B$KH<XV844451 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
